-

Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to two upcoming webcasts of Pfizer discussions at healthcare conferences:

  • Annaliesa Anderson, SVP & Head, Vaccines Research & Development; and Rodrigo Puga, U.S. Commercial and Global Business Lead for Internal Medicine, at the Wells Fargo 2023 Healthcare Conference on Wednesday, September 6, 2023 at 12:45 p.m. EDT.
  • Mikael Dolsten, Chief Scientific Officer & President, Pfizer Research and Development, at Citi's 18th Annual BioPharma Conference on Thursday, September 7, 2023 at 10:30 a.m. EDT.

To view and listen to the webcasts, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcasts will be available at www.pfizer.com/investors beginning today.

The transcripts and webcast replays of the discussions will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussions and will be accessible for at least 90 days.

About Pfizer: Breakthroughs That Change Patients’ Lives

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Disclosure Notice: The webcasts may include forward-looking statements about, among other things, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics and size, growth, performance, timing of exclusivity and potential benefits, our anticipated operating and financial performance, reorganizations, business plans, strategy and prospects; strategic reviews; capital allocation objectives; plans for and prospects of our acquisitions, dispositions and other business development activities, and our ability to successfully capitalize on these opportunities; manufacturing and product supply; and our efforts to respond to COVID-19, including our COVID-19 products, that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.. A description of these risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

The forward-looking statements in each webcast speak only as of the original date of the webcast. Pfizer assumes no obligation to update forward-looking statements contained in the webcasts as the result of new information or future events or developments.

Category: Finance

Contacts

Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Contact:
IR@Pfizer.com
+1 (212) 733-4848

Pfizer Inc.

NYSE:PFE

Release Versions

Contacts

Media Contact:
PfizerMediaRelations@Pfizer.com
+1 (212) 733-1226

Investor Contact:
IR@Pfizer.com
+1 (212) 733-4848

More News From Pfizer Inc.

Pfizer Reports Strong First-Quarter Results And Reaffirms 2026 Guidance

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2026 and reaffirmed its full-year 2026 financial guidance(2). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: “We're off to a strong start in 2026, and it reinforces our confidence that we will successfully navigate this defining period for Pfizer. Our R&D pipeline is advancing on multiple fronts – with positive Phase 3 readouts and encouraging mid-stage results buildin...

Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression‑free survival (PFS), as assessed by blinded independent central review (BICR), v...

Pfizer Reaches Three Settlement Agreements for VYNDAMAX

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX® (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective U.S. patent expiry date for VYNDAMAX to J...
Back to Newsroom